[Federal Register Volume 63, Number 85 (Monday, May 4, 1998)]
[Notices]
[Pages 24558-24559]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-11742]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Dental Plaque Subcommittee of the Nonprescription Drugs Advisory
Committee; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: Dental Plaque Subcommittee of the
Nonprescription Drugs Advisory Committee.
General Function of the Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on May 27, 28, and 29,
1998, 8:30 a.m. to 5 p.m.
Location: Holiday Inn, Two Montgomery Village Ave., Gaithersburg,
MD.
Contact Person: Robert L. Sherman or Stephanie A. Mason, Center for
Drug Evaluation and Research (HFD-560), Food and Drug Administration,
5600 Fishers Lane, Rockville, MD, 301-827-5191, or FDA Advisory
Committee Information Line, 1-800-741-8138 (301-443-0572 in the
Washington, DC area), code 12541. Please call the Information Line for
up-to-date information on this meeting.
Agenda: On May 27, 1998, the subcommittee will discuss: (1) The
safety and effectiveness of the combination of stannous pyrophosphate
and zinc citrate; (2) the effectiveness of the combination of hydrogen
peroxide, sodium lauryl sulfate, sodium citrate and zinc chloride; (3)
the safety and effectiveness of hexetidine, soluble pyrophosphate,
nonsaponifiable fraction of corn oil, bromchlorophene and chlorhexidine
digluconate; and (4) final formulation testing. On May 28, 1998, the
subcommittee will discuss labeling
[[Page 24559]]
of over-the-counter antiplaque-antigingivitis drug products. On May 29,
1998, the subcommittee will discuss recommended therapeutic
combinations for antiplaque-antigingivitis drug products.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person by May 20, 1998.
Oral presentations from the public will be scheduled between
approximately 8:30 a.m. and 12 m. on May 27, 28, and 29, 1998. Time
allotted for each presentation may be limited. Those desiring to make
formal oral presentations should notify the contact person before May
20, 1998, and submit a brief statement of the general nature of the
evidence or arguments they wish to present, the names and addresses of
proposed participants, and an indication of the approximate time
requested to make their presentation.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: April 24, 1998.
Michael A. Friedman,
Deputy Commissioner for Operations.
[FR Doc. 98-11742 Filed 5-1-98; 8:45 am]
BILLING CODE 4160-01-F
